U.S. market Closed. Opens in 1 hour 58 minutes

EGRX | Eagle Pharmaceuticals, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for EGRX we got that it has average fundamentals where Valuation is considered to be significantly undervalued, Profitability is moderate, Growth is bad and Health is passable.

Valuation (100%)

Company Industry
P/E Ratio (TTM) 0.25 17.20
PEG Ratio (TTM) 0.00 -22.43
P/S Ratio (TTM) 0.03 5.37
P/B Ratio (TTM) 0.04 4.26
P/FCF Ratio (TTM) 0.29 8.29
Price to 5YR AVG Earnings Ratio 0.87 27.96
Price to 5YR AVG FCF Ratio 0.21 20.91

Profitability (60%)

Company Industry
ROA (TTM) 8.78% 2.56%
ROE (TTM) 17.39% 16.24%
Net Profit Margin (TTM) 11.26% -12.96%
ROIC 5YR AVG 19.19% 9.81%

Growth (47%)

4QTR AVG 3YR AVG 5YR AVG
EPS 88.83% -34.50% 48.11%
Revenue -3.07% -7.39% 10.75%
Net Income 88.87% -36.65% 46.25%
Cash Flow 40.83% -15.90% -1.46%

Health (53%)

Company Industry
Current Ratio (TTM) 1.70 2.48
Quick Ratio (TTM) 1.27 1.84
D/E Ratio (TTM) 0.27 -0.30
Interest Coverage (TTM) 13.21 11.70
Piotroski F-Score 5 6
Altman Z-Score 1.71 4.60
LTL to 5YR AVG FCF 1.32 4.63
Shares Outstanding Growth 5YR AVG -3.03% 29.98%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙